Ocular Therapeutix (FRA:0OT) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:0OT Ocular Therapeutix Inc FRA:0OT
51 GF Score
Price €8.60
GF Value €3.89
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Ocular Therapeutix Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ocular Therapeutix's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:0OT vs AUPH, NTLA, TYRA: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocular Therapeutix Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Margin of Safety % (DCF Earnings Based) falls into.


FRA:0OT
51GF Score
Ocular Therapeutix Inc FRA:0OT
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of €8.60 is trading 121.1% above its estimated GF Value™ of €3.89. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for FRA:0OT:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €3.89 vs. price of €8.60 (121.1% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocular Therapeutix Business Description

Other Exchanges OCUL:USA0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score

Get the complete analysis for FRA:0OT

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.60
Price
€3.89
GF Value